Project Details
Description
Host cell protein impurities in biopharmaceuticals may cause severe side effects. Today´s commercial ELISA can generally only monitor 30-70% of the host cell proteins in a drug sample, and provide no information about identity
of these host cell proteins. We will deliver an innovative analysis service, enabling identification and relative quantification of individual host cell proteins, and selection of 2-3 commercial ELISA that in combination can monitor all host cell proteins in a drug sample.
of these host cell proteins. We will deliver an innovative analysis service, enabling identification and relative quantification of individual host cell proteins, and selection of 2-3 commercial ELISA that in combination can monitor all host cell proteins in a drug sample.
| Status | Finished |
|---|---|
| Effective start/end date | 01/04/2017 → 31/05/2019 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.